Ocular abnormalities in chronic schizophrenia: Clinical implications

Australian and New Zealand Journal of Psychiatry

Volumn 31, Issue 2, 1997, Pages 252-256

  Smith, Deidre ^b   Pantelis, Christos ^a,b,c   McGrath, John ^d   Tangas, Christine ^e   Copolov, David ^b  

^a Dept of Cognitive Neuropsychiatry ^*

^b FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d WOLSTON PARK HOSPITAL   (Australia)

^e ROYAL VICTORIAN EYE AND EAR HOSPITAL   (Australia)

Author keywords

Chronic schizophrenia; Eye toxicity; Neuroleptics

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; ARTICLE; CATARACT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORNEA DISEASE; DOUBLE BLIND PROCEDURE; EYE TOXICITY; FEMALE; HUMAN; MALE; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; VISUAL ACUITY;

EID: 0030911573     PISSN: 00048674     EISSN: None     Source Type: Journal    
DOI: 10.3109/00048679709073828     Document Type: Article

References (42)

1. Walsh FB, Hoyt WF. Clinical neuro-ophthalmology. 3rd ed. Baltimore: Williams & Wilkins, 1969.
2. Scheic HG, Albert DM Textbook of ophthalmology. 9th ed. Philadelphia: Saunders, 1977.
3. Grant WM, Schuman JS Toxicology of the eye. 4th ed. Illinois: Charles C. Thomas, 1993
4. Mathalone MBR. Eye and skin changes in psychiatric patients treated with chlorpromazine. British Journal of Ophthalmology 1967; 51:86-93.
5. DeLong SL. Incidence and significance of chlorpromazine eye changes. Diseases of the Nervous System 1968; 29(Suppl.):19-22.
6. Baron JB, Morel R Rivoalan Y, Foulairac A. Ocular side effects of prolonged treatment with chlorpromazine associated or not with skin complications. Agressologie 1968; 9:293-304.
7. Baron JB, Morel P, Rivoalan Y. Long term evolution of the lens opacities induced by chlorpromazine prolonged therapy. Agressologie 1971; 12:57-60.
8. Boet DJ. Toxic effects of phenothiazines in the eye. Documenta Ophthalmalogica 1970; 28:1-69.
9. Kalberer M, Atar Z, Bider E. On eye changes in long-term treatment with largactil. Ophthalmologica 1970; 161:118-124.
10. Mason CG. Ocular accumulation and toxicity of certain systemically administered drugs. Journal of Toxicology and Environmental Health 1977; 2:977-995.
11. Gerhard J, Franck H, Sommer S, Mack G. Ophthalmologic side effects of treatment with phenothiazines. Revue d'Oto-Neuro-Ophthalmologie 1975; 47:71-77.
12. Issac NE, Walker AM, Jick H, Gorman M. Exposure to phenothiazine drugs and risk of cataract. Archives of Ophthalmology 1991; 109:256-260.
13. Deluise V, Flynn JT. Asymmetric anterior segment changes induced by chlorpromazine. Annals of Ophthalmology 1981; 13:953-955.
14. Howard RO, McDonald CJ, Dunn B, Creasey WA. Experimental chlorpromazine cataracts. Investigative Ophthalmology 1969; 8:412-421.
15. Baum JL. The effect of chloroquine, chlorpromazine and ultraviolet radiation on the corneas of pigmented rabbits. Acta Ophthalmologica 1972; 50:18-25.
16. Mitchell AC, Brown KW. Chlorpromazine-induced retinopathy. British Journal of Psychiatry 1995; 166:822-823.
17. Zelickson AS, Zeller HC. A new and unusual reaction to chlorpromazine. Journal of the American Medical Association 1964; 188:394-396.
18. Henkes HE. Fenothiazine-retinopathy. Nederlands Tijdschrift voor Geneeskunde 1966; 110:789-790.
19. Siddall JR. Ocular toxic changes associated with chlorpromazine and thioridazine. Canadian Journal of Ophthalmology 1966; 1:190-198.
20. Siddall JR. Ocular complications related to phenothiazines. Diseases of the Nervous System 1968; 29(Suppl ):10-13.
21. Nouri A, Ceundet JF. Ocular side effects in the course of prolonged treatment with neuroleptics Schweizerische Medizinische Wochenschrift 1968; 98:1708-1711.
22. Petrohelos MA, Tricoulis D. Ocular complications of chlorpromazine therapy. Ophthalmologica 1969; 159:31-38.
23. Segal RL, Rosenblatt S, Eliasoph I. Endocrine exophthalmos during lithium therapy of manic-depressive disease. New England Journal of Medicine 1973; 289:136-138.
24. Saul RF, Hamburger HA, Selhorst JB. Pseudotumor cerebri secondary to lithium carbonate. Journal of the American Medical Association 1985; 253:2869-2870.
25. Bourgeois JA. Ocular side effects of lithium - a review. Journal of the American Optometric Association 1991; 62:548-551.
26. O'Farrell TJ, Connors GJ, Upper D. Addictive behaviours among hospitalised psychiatric patients. Addictive Behaviours 1983; 8:329-333.
27. The Eye Disease Case-Control Study Group. Risk factors for neo-vascular age-related macular degeneration. Archives of Ophthalmology 1992; 110:1701-1708.
28. Prummel MF, Wiersinga WM. Smoking and risk of Graves disease. Journal of the American Medical Association 1993; 269:479-482.
29. Westermeyer J. A third case of self-enucleation. American Journal of Psychiatry 1972; 129:144.
30. Rosen DH, Hoffman AM. Focal suicide- self-enucleation by two young psychotic individuals. American Journal of Psychiatry 1972; 128:123-128.
31. MacLean G, Robertson BM. Self-enucleation and psychosis. Archives of General Psychiatry 1976; 33:242-249.
32. Tapper CM, Bland RC, Danyluk L. Self-inflicted eye injuries and self-inflicted blindness. Journal of Nervous and Mental Disease 1979; 167:311-314.
33. Ananth J, Kaplan HS, Lin K. Self-inflicted enucleation of an eye: two case reports. Canadian Journal of Psychiatry 1984; 29:145-146.
34. Clark, RA. Self-mutilation accompanying religious delusions: a case report and review. Journal of Clinical Psychiatry 1981; 42:243-244.
35. Jones NP. Self-enucleation and psychosis. British Journal of Ophthalmology 1990; 74:571-573.
36. Nelson HE, Pantelis C, Carruthers K, Speller J, Baxendale S. Barnes TRE. Cognitive functioning and symptomatology in chronic schizophrenia. Psychological Medicine 1990; 20:357-365.
37. Lieberman AA. Coburn AF The health of the chronically mentally ill: a review of the literature. Community Mental Health Journal 1986; 22:104-116.
38. Farmer S. Medical problems of chronic patients in a community support program. Hospital and Community Psychiatry 1987; 38:745-749.
39. Schwab B, Drake RE, Burghardt E. Health care of the chronically mentally ill: the culture broker model. Community Mental Health Journal 1988; 24:174-184.
40. Allodi F, Cohen M. Physical illness and length of psychiatric hospitalisation. Canadian Psychiatric Association Journal 1978; 23:101-106.
41. Koranyi EK Morbidity and rate of undiagnosed physical illnesses in a psychiatric clinic population. Archives of General Psychiatry 1979; 36:414-419.
42. Tessler RC, Manderscheid RW Factors affecting adjustment to community living. Hospital and Community Psychiatry 1982; 33:203-207